==== Front J Fungi (Basel) J Fungi (Basel) jof Journal of Fungi 2309-608X MDPI 33050302 10.3390/jof6040213 jof-06-00213 Review Novel Antifungal Agents and Their Activity against Aspergillus Species Vahedi-Shahandashti Roya https://orcid.org/0000-0002-2946-7785Lass-Flörl Cornelia * Institute of Hygiene and Medical Microbiology, Medical University Innsbruck, 6020 Innsbruck, Austria; Roya.Vahedi@i-med.ac.at * Correspondence: cornelia.lass-floerl@i-med.ac.at 09 10 2020 12 2020 6 4 21308 9 2020 07 10 2020 © 2020 by the authors.2020Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).There is a need for new antifungal agents, mainly due to increased incidence of invasive fungal infections (IFI), high frequency of associated morbidity and mortality and limitations of the current antifungal agents (e.g., toxicity, drug–drug interactions, and resistance). The clinically available antifungals for IFI are restricted to four main classes: polyenes, flucytosine, triazoles, and echinocandins. Several antifungals are hampered by multiple resistance mechanisms being present in fungi. Consequently, novel antifungal agents with new targets and modified chemical structures are required to combat fungal infections. This review will describe novel antifungals, with a focus on the Aspergillus species. novel antifungal drugsnew therapiesinvasive fungal infectionsaspergillosis ==== Body 1. Introduction Invasive fungal infections (IFI) are responsible for over one million deaths annually, which is a significant global health problem [1,2]. This is mainly due to the increasing number of immunocompromised individuals with altered immune function including primary immune deficiency, cancer chemotherapy, HIV/AIDS, hematologic and solid organ transplantation, prematurity, and immune-modulatory medications [3,4,5]. The number of at-risk patients and improved diagnostic techniques resulted in an alarming rise in the number of reported fungal infections [6,7]. Invasive aspergillosis, an infection caused by fungi of the Aspergillus taxon, remains a significant threat, particularly in immunosuppressed patients [8]. The most prevalent Aspergillus species are A. fumigatus, A. flavus, A. terreus, and A. niger [9]. Aspergillus spp. have the capacity to cause a broad range of clinical diseases, from mild and superficial infections, to life-threatening and invasive illnesses with more than 80% mortality rate [10,11]. Pulmonary aspergillosis is considered the most prevalent manifestation of invasive aspergillosis [12]. Antifungal drug discovery has been stagnant in the past. Hence, therapeutic possibilities for IFI are limited [13]. There are currently four major classes of antifungal agents used in the treatment of systemic mycoses: polyenes, azoles, echinocandins and flucytosine [14]. These antifungals have several limitations such as toxicity, drug–drug interactions, variable pharmacokinetics, and reduced bioavailability. The emergence of drug resistance has introduced further limitations [15]. Voriconazole is recommended for first-line treatment followed by liposomal amphotericin B and isavuconazole [16,17]. The rate of azole-resistant Aspergillus isolates has increased noticeably, contributing to therapeutic failures [18]. The prevalence of azole-resistant clinical isolates of Aspergillus spp. has reached 30% in some regions in Europe, with data outside Europe varying between 0.6% and 11.2% [19]. In this review, we evaluate new antifungal compounds and natural products with a focus on Aspergillus spp. Additionally, potential new pathways will be discussed as promising targets. 2. Improving Existing Antifungals This part will briefly address new formulations of existing antifungals, which are active against Aspergillus spp. A summary of agents is given along with their mechanism of action, in vitro activity, and clinical trial phase in Table 1. An overview of different fungal targets is given in Figure 1. 2.1. CD101 CD101 (Cidara Therapeutics) (Biafungin) (Rezafungin), a novel structurally formulated echinocandin, for both intravenous and oral use, is a cyclic hexapeptide with a choline moiety at the C5 ornithine position [54]. This drug is presently in phase III human clinical trials. Echinocandins act as inhibitors of the 1, 3-β-d-glucan synthase enzyme complex, which play a role in the synthesis of fungal cell walls [55]. Compared with other echinocandins, the advantage of CD101 over existing echinocandin drugs lies in its pharmacokinetics. The distinct structural feature of CD101 confers improved stability, resulting in an extended half-life and an enhanced safety profile [54,55,56]. Relative to the 24 h half-life of anidulafungin, CD101 has a half-life of approximately 130h in humans [57]. CD101 is being developed as a weekly intravenous drug for the treatment and prevention of IFI, replacing the daily doses currently available [54]. Compared to other echinocandins, CD101 has shown an enhanced in vitro potency with minimum effective concentrations 90 (MEC90) of ≤0.008–0.03 μg/mL against Aspergillus spp., wild-type and azole non-wild-type isolates, including A. fumigatus (minimum inhibitory concentration (MIC)50/90, ≤0.008/0.015 μg/mL), A. terreus (MIC50/90, 0.015/0.015 μg/mL), A. niger (MIC50/90, ≤0.008/0.03 μg/mL) and A. flavus (MIC50/90, ≤0.008/≤0.008 μg/mL) [58]. Rezafungin showed in vivo efficacy in a neutropenic murine model with disseminated infection caused by A. fumigatus (ATCC 13073), providing 10-day survival rates with a one-time dose of 2 mg/kg [66]. 2.2. SCY-078 (Formerly MK-3118) SCY-078 (Scynexis), a class of semisynthetic derivative of the natural product enfumafungin, is a first-in-class orally formulated inhibitor of active β-1,3-glucan synthase, with in vitro and in vivo activity against Aspergillus spp. [59,60]. This drug is now in phase III of clinical trials. β-1,3-d-glucan synthase is a unique membrane-associated protein complex in fungi that require the synthesis of the main constituent of the cell wall, β-1,3-d-glucan polymers. Echinocandins also target the fungal cell wall by blocking β-1,3-d-glucan synthase, but SCY-078 is structurally distinct from the currently available echinocandins, constricting its effectiveness to echinocandin-resistant Aspergillus spp. [61,67,68,69]. In vitro activity of SCY-078 demonstrates a promising potency against the Aspergillus spp. complex, with the MEC90/MIC90 value (μg/mL) levels remaining below 0.5 µg/mL, for A. fumigatus (0.25 µg/mL), A. terreus (0.12 µg/mL), A. flavus (0.12 µg/mL) and A. niger (0.06 µg/mL) [60,61]. The efficacy of SCY-078 has further been shown in a neutropenic mouse model of invasive aspergillosis caused by wild type and azole-resistant A. fumigatus strains, leading to an increased survival rate at 15 mg/kg/day and 20 mg/kg/day [70]. 2.3. Amphotericin B (AMB) Renovated Structure AMB-deoxycholate has a potent wide-spectrum fungicidal activity, which prompted the development of safer and more effective derivatives. The mode of action of AMB remains unclear, but it is generally believed that it acts via two major mechanisms: an increase in permeation by binding to the ergosterol of fungal membrane, forming trans-membrane channels leading to leakage of cell constituents and a pro-oxidant effect causing oxidative damage in target fungal cells [35,36]. The affinity of AMB to ergosterol-containing membranes is stronger than cholesterol-containing membranes. However, it also has the ability to bind to cholesterol, leading to toxicity in mammalian cells. To develop a soluble and less-toxic formula, AMB has been structurally modified and conjugated with various soluble macromolecules such as nanoparticle suspensions and conjugated polysaccharides (AMB-arabinogalactan or AMB-polyethylene glycol), leading to lower toxicity and high efficacy in vivo [40,41,42,43,44]. Alternative structures might have different strategies for improving the cellular selectivity or accessing certain body compartments to reduce membrane toxicity of AMB [37]. One proposed mechanism is through minimizing the disruptive power of aggregated forms by attaching to an umbrella-derived molecule and increasing the selectivity of AMB to target fungi [37]. Unlike the existing formulations of AMB, which are only approved for intravenous injection, an oral drug delivery consisting of AMB cochleate lipid–crystal nanoparticles (Matinas BioPharma) is a remarkable improvement as it is structurally more stable against degradation by the gastrointestinal tract [38,39]. AMB cochleate is made up of phosphatidylserine with phospholipid-calcium precipitates, constructing a multilayered structure with a solid, lipid bilayer, with no inner aqueous space [39]. In vivo, orally administered AMB-cochleate has shown high efficacy in a murine model of systemic aspergillosis resulting in 70% survival rates (20 and 40 mg/kg/day of body weight/day for 14 days) [71]. This drug is now in phase II of clinical trials (NCT02971007 and NCT02629419). 3. New Antifungal Compounds with Novel Targets in Aspergillus The focus of this section describes targets and mechanisms of action of new anti-Aspergillus compounds that have reached the early stages of human clinical testing. 3.1. T2307 T-2307 or 4-{3-[1-(3-{4-[amino(imino)methyl] phenoxy} propyl) piperidin-4-yl] propoxy} benzamidine is a novel arylamidine structure that belongs to the category of aromatic diamidines and is synthesized by the Toyama Chemical Company [20]. In 2015, phase I safety trials in healthy young and elderly volunteers were examined. (clinicaltrials.gov Identifier: NCT02289599). The specific structure of the amidine (functional group) of T-2307 is associated with its distinct mechanism of action [72]. In Candida albicans, this component is selectively transported in through a high-affinity spermine and spermidine transportation system (polyamine transporters) regulated by Agp2 [21]. The high affinity of transporters in C. albicans for T-2307 compared to other diamidines such as pentamidine, leads to different rates of uptake, which may lead to the different in vitro antifungal activities [22]. Furthermore, the selectivity of the mechanism of action of T-2307 in fungal and mammalian cells may reflect the high affinity with fungal mitochondria. Once it accumulates inside the fungal cells, T-2307 results in the collapse of the mitochondrial membrane respiration potential, eventually leading to fungicidal activity [73]. T-2307 exhibits broad-spectrum activity against most of the clinically relevant pathogenic yeasts and filamentous fungi including Aspergillus spp., Candida spp., and Cryptococcus neoformans, with notably low MICs [20]. The MIC of T-2307 against Aspergillus spp. ranged from 0.0156 to 1 μg/mL, which is similar to those of voriconazole and micafungin. However, T-2307 indicates fungicidal activity against A. nidulans and A. niger (0.0313 to 0.0625 μg/mL) whereas it is categorized as fungistatic against other Aspergillus spp. (4 to >64 μg/mL). In vivo activity in a murine model with systemic infection caused by A. fumigatus resulted in more than 80% survival rate (1 mg/kg). Nevertheless, T-2307 in a disseminated candidiasis mouse model was more effective than micafungin and amphotericin B but in a disseminated aspergillosis mouse model was comparable to the activities of micafungin and amphotericin B [20]. 3.2. Fosmanogepix (APX001) APX001 (formerly E1210, 2-amino-3-(3-{4-[(pyridine-2-yloxy) methylbenzyl}-1-2-isoxazol-5-yl) pyridinium-1-yl] methyl hydrogen phosphate) is a small cell wall-active antifungal compound discovered by Eisai Company (Tokyo, Japan), which is being synthesized by Amplyx Pharmaceuticals, SanDiego, CA. APX001, an N-phosphonooxymethyl, is a prodrug that is rapidly broken down by systemic alkaline phosphatases to the active component, APX001A [23,74]. Phase 1 clinical trials have shown safety in both healthy volunteers and patients with severe leukemia [74]. Phase II studies are ongoing. E1210/APX001 demonstrates selective antifungal activity by inhibiting fungal adhesion and invasion. Glycosylphosphatidylinositol (GPI) cell wall anchor proteins, known as mannoproteins, display various functions ranging from enzymatic activity, signaling, cell adhesion, cell wall metabolism, and immune response [75]. In C. albicans, GPIs mediate cross-linking of cell wall mannoproteins to β-1,6-glucan, preserve the integrity of the fungal cell wall and play a role in adhesion. APX001 targets the fungal enzyme GPI-anchored wall transferase (Gwt1), subsequently inactivating an early step of posttranslational modification of GPI anchor proteins [24,76,77]. Since Gwt1 catalyzes the inositol acylation of fungus-specific GPI, Gwt1 inhibition leads to the disruption of GPI-anchored protein maturation. A lack of these proteins in C. albicans revealed that the cell wall weakens, resulting in β-1, 3-glucan exposure, hyphal growth suppression and increase in the recognition of the fungus by immune cells [25]. Interestingly, even though mammals possess the Gwp1 homolog gene, PigW, E1210 is only active against fungal Gwt1ps. E1210 has no inhibitory effect on human inositol acylation, rendering it an effective therapeutic target for fungal infections [25]. APX001A is active against a broad range of pathogenic yeast and molds, including Aspergillus spp., Fusarium spp., and black molds [24]. The in vitro activity of E1210 and comparator antifungal agents (e.g., caspofungin, itraconazole, posaconazole and voriconazole) against wild-type, polyene- and triazole-resistant strains of Aspergillus spp., including A. flavus, A. fumigatus, A. niger, A. terreus exhibited an exceptional potency in vitro (i.e., MIC≤0.06 μg/mL) [24]. Compared to reference antifungals (e.g., voriconazole, caspofungin, liposomal amphotericin B), E1210 showed higher efficacy and improved survival rate in murine pulmonary aspergillosis models [78]. Animal models (rats and monkeys) indicate that APX001 was rapidly absorbed and widely distributed for oral and intravenous administration [78]. 3.3. ASP2397 (VL-2397) ASP2397 is a cyclic hexapeptide natural antifungal compound, cyclo{Asn-Leu-dPhe-[(N5-acetyl-N5-hydroxyOrn)3]-} Al(III), derived from Acremonium persicinum [26]. In a phase I study, healthy volunteers who received single or multiple intravascular doses of increasing concentrations displayed adequate tolerance of up to 1200 mg without any accumulation [79]. Phase II clinical trials (registration no. NCT03327727) focused on the treatment of patients with acute leukemia suffering from invasive aspergillosis and bone marrow transplantation. However, this study was prematurely terminated due to a financial decision [80,81]. ASP2397 has the ferrichrome type siderophore structure, a low-molecular-weight siderophore with high specificity for iron [82]. Siderophores (iron chelators) are produced by microorganisms in response to iron deficiency. Under iron-deficient conditions, they increase their uptake of iron by enhancing the expression of the siderophore transporter [83,84]. The exact mechanism of ASP2397 within fungal cells remains unknown. Nevertheless, ASP2397 is believed to localize within fungal cells, such as A. fumigatus, via the uptake of siderophore iron transporter 1 (Sit1) [27]. It is shown that the presence of an iron chelator in medium intensifies the potent antifungal activity of ASP2397 against Aspergillus spp. Hence, the study proposes the uptake of ASP2397 by specific siderophore iron transporter 1 (Sit1) in A. fumigatus as a potential antifungal therapeutic approach. Inactivation of Sit1 results in resistance to ASP2397 [85]. Complementary investigations revealed that an additional intracellular target of ASP2397 probably exists. This may be explained by the observation that AS2524371, an ASP2397 analog with a similar siderphore structure, with the exception of an amino acid substitution (Gly-Ser-Gly replaces Asn-Leu-dPhe), has no antifungal activity against A. fumigatus [26]. The in vitro testing of ASP2397 showed excellent fungicidal efficacy against most Aspergillus spp., including wild-type strains as well as azole-resistant mutants of A. fumigatus, A. terreus, A. flavus and A. nidulans. With the exception of A. niger, the MIC ranged between 1 to 4 μg/mL in human serum [27,85]. In contrast to liposomal amphotericin B and azoles (voriconazole and posaconazole), ASP2397 has a faster and more effective fungicidal activity in vitro. This fungicidal activity has also been observed against germinated conidia of some Aspergillus spp. in vitro in human serum, suggesting that it may produce more suitable therapeutic outcomes for patients with invasive aspergillosis [27]. Remarkably, ASP2397 showed excellent in vitro efficacy against wild-type strains as well as azole-resistant mutants of A. fumigatus (Cyp51A). However, MICs of both ASP2397 and azoles were elevated in the isolate of A. terreus with M217I CYP51A mutation [28]. Compared to A. fumigatus, higher MIC of ASP2397 in A. terreus isolates may suggest that it is less effective against this species. Since CYP51A is not the target of ASP2397, further studies are required to investigate the underlying mechanisms behind the MIC elevation against mutant A. terreus isolate. The effect of delayed treatment of ASP2397 in an in vivo mouse model of invasive aspergillosis showed a high survival rate (100% survival), compared to posaconazole (40% survival rate) [27]. Given that ASP2397 has no target in mammalian cells, and possesses distinct modes of antifungal mechanisms compared to azoles and amphotericin B, it is hypothesized that ASP2397 will have selective fungal toxicity and could be a promising substitute for the treatment of azole-resistant Aspergillus infections. 3.4. F901318 (F2G) or Olorofim F901318, a representative member of a novel class of antifungal drugs, the orotomides, clinically exhibits exceptional potency against a broad range of dimorphic and filamentous fungi, particularly Aspergillus spp. [29]. It is currently in phase III of clinical trials and in phase II as an oral and intravenous agent with a specific emphasis on aspergillosis (NCT0286178). The novel mechanism of action of F901318 is well described in A. fumigatus [29]. It targets the dihydroorotate dehydrogenase (DHODH) enzyme, which in Aspergillus spp. is encoded by the pyre gene. DHODH is an oxidoreductase enzyme that catalyzes the fourth step of the de novo pyrimidine biosynthesis pathway, the reduction of dihydroorotate to orotate. Pyrimidines are crucial subunits for the synthesis of DNA and RNA and for the formation of precursors for lipid and carbohydrate metabolism. Despite the presence of a mammalian version of the enzyme, F901318 has differential inhibitory activity. It is 2000-fold more potent against fungal DHODH than the mammalian enzyme homolog. Supplementary protein kinetic experiments demonstrated that F901318 is a reversible inhibitor of A. fumigatus DHODH, which competitively inhibits the ubiquinone (coenzyme Q) cofactor [29]. This compound with such a unique target displayed potent in vitro and in vivo activity against several medically relevant molds, including several Aspergillus spp. However, it is not effective against Mucorales, C. neoformans and Candida spp. [29,30,31,32]. The lack of activity against Candida spp., C. neoformans, and Mucorales is due to a phylogenetically distant DHODH, although olorofim susceptible organisms are classified together under the same DHODH phylogenetic tree [29]. F901318 demonstrates efficacy against Aspergillus spp., regardless of species and methods used, which is of significant importance given the increased prevalence of azole-resistant Aspergillus spp. [86,87]. MIC ranges of F901318 (0.002–0.063 μg/mL) against Aspergillus spp. including A. fumigatus (azol-resistant and non-azole resistant strains), A. terreus, A. flavous, A. nidulans, A. tubingensis and A. tubingensis are relatively low compared to MICs of various azoles and amphotericin B [30,31]. Resistance induction to olorofim assessed by serial passage and drug gradients has no influence, at least on A. fumigatus [29]. The efficacy of olorofim therapy (15 mg/kg, three times per day) against infection with A. fumigatus, A. nidulans and A. tanneri in both neutropenic and chronic granulomatous disease (CGD) mouse models exhibited promising therapeutic outcomes. A 10-day survival rate of 80% to 88% and 63% to 88% in the neutropenic mouse model and CGD mouse model was reported, respectively [87]. The narrow-spectrum activity of F901318 forces an additional study design with the use of another antifungal until the specific diagnosis of aspergillosis is reached. 3.5. VT-1598 VT-1598, an investigational tetrazole from Viamet Pharmaceuticals, is a selective fungal cytochrome P51 (CYP51) enzyme inhibitor with clinically significant reduced drug–drug interactions. This compound is currently in phase I of clinical trials [33]. Two main limitations of azole class antifungals reinforced this developing new formulation: non-selective activity and drug–drug interaction of the members of this class. Azoles generally inhibit fungal 14α-lanosterol demethylase (aka Cyp51), a key cytochrome P450 enzyme (CYP450) in ergosterol biosynthesis, resulting in a deficiency of ergosterol and accumulation of toxic 14α-methylated sterols in membranes [88]. Furthermore, azoles can hinder other cytochrome P450 enzymes, conducting non-specific activity of this class of antifungals. The clinical concentrations of some azoles can be influenced by drugs that inhibit or induce the activity of CYP 450 enzymes since some azoles are substrates of these enzymes. In A. fumigatus, VT-1598 is a structurally distinct CYP51 inhibitor in that its triazole metal-binding group is substituted with tetrazole, resulting in more specific inhibition of fungal Cyp 51 enzymes [89]. The X-ray molecular structure of a VT-1598/A. fumigatus CYP51 complex has explained that the improved hydrogen bond between the phenoxymethyl oxygen of VT-1598 and the imidazole ring nitrogen of His374 of CYP51 residue is associated with maximal efficacy and broad-spectrum activity of VT-1598 [90]. VT-1598 demonstrated a comparable in vitro activity against Aspergillus spp. with similar geometric mean (GM) MICs to those posaconazole and voriconazole for A. flavus (0.685 μg/mL), A. niger (1.78 μg/mL) and A. terreus (0.533 μg/mL) [34]. In contrast, wild-type isolates of A. fumigatus showed higher GM MICs ranges of VT-1598 (0.25–2 μg/mL) in comparison to those of posaconazole and voriconazole. However, the GM MICs of VT-1598 against A. fumigatus CYP51A mutants with elevated posaconazole and voriconazole MICs showed a noticeably reduction (13.3 μg/mL). An in vivo 12-day survival study in a disseminated mouse model of invasive aspergillosis showed 100% survival at 20 and 40 mg/kg with a suppressed fungal burden [91]. 4. Potential Pathways as Targets against Aspergillus The following studies discuss fungal molecules displaying potential targets for developing new antifungal agents with limited or no damage to host cellular functions. 4.1. Calcium–Calcineurin Signaling Network Calcium signal transduction in fungi has gained importance due to its crucial role in the survival and adaptation of fungi. Calcium, a second messenger molecule, plays direct roles in fungal physiological processes, mediates stress responses, and promotes virulence [92,93,94,95,96]. Calcineurin, one of the regulators of calcium homeostasis with a subtle structural difference in fungi compared to humans, is a potential target of selective inhibitors that could potentially be used in antifungal therapy [45]. Calcineurin, a conserved Ca2+-calmodulin (CaM) activated protein phosphatase 2B, belongs to the phospho-protein phosphatase family. The stress response in the fungal cell, including Saccharomyces cerevisiae and Schizosaccharomyces pombe is initiated by Ca2+ uptake, which then binds to the binding sites of calmodulin. After a conformational transition, Ca2+-bound calmodulin forms a ternary complex together with the calcineurin subunits, CnA and CnB. The calmodulin–CnA–CnB complex acquires a phosphatase activity and dephosphorylates the transcription factor Crz1. Genes activated by dephosphorylized Crz1 are involved in calcium-dependent signaling and regulation of several essential cellular processes in many pathogenic fungi including growth, septation, morphological states transition, cell wall integrity, virulence, stress responses, and drug resistance [46,97]. Furthermore, calcineurin is associated with heat shock protein 90 (Hsp90) and histone deacetylases (HDACs, also referred to as lysine deacetylases, KDACs). The molecular chaperone Hsp90 activates its target protein, calcineurin phosphatase, which plays a key role in stress responses and cell wall repair mechanisms induced by antifungals exposure [98,99,100]. The mechanisms displayed by calcineurin instigate the emergence and maintenance of drug resistance in various fungal species [101,102]. HDACs play an essential role in fungal virulence by controlling the expression and function of multiple proteins, including chaperones, such as Hsp90, and secondary metabolites that are important for basal growth or stress adaptation [103]. Hsp90 has been identified to have a principal role in the acquisition and evolution of resistance to azoles and echinocandins. Importantly, growing evidence suggests that this inherent resistance mechanism is mediated via calcineurin [101,104,105,106]. Therefore, targeting the Hsp90–calcineurin axis may be a promising antifungal strategy and enhance the activity of different classes of antifungal drugs, such as the cell-wall-acting echinocandins and the ergosterol biosynthesis inhibitor azoles. Several studies have demonstrated that immunosuppressive drugs exert antifungal effects against a variety of pathogenic fungi by inhibiting calcineurin signaling network and related components. Although these compounds are all currently in clinical use as immunosuppressive therapy and anti-proliferative agents, the potent immunosuppressive activity of these drugs hindered their expansion as antifungal agents. Thus, the following section analyzes some immunosuppressive drugs which have the potential to play a role in antifungal therapy. 4.1.1. Tacrolimus (FK506) Tacrolimus (FK506 or Fujimycin), a macrolide lactone extracted from Streptomyces tsukubaensis, is commonly used as an immunosuppressive drug in transplantation [107]. The potential mechanism of tacrolimus in A. fumigatus is suggested through its binding to the intracellular protein FKBP12, preventing the calcineurin signal pathway, a principal component in the regulation of intracellular Ca2+ concentration [46]. The FKBP12–tacrolimus complex suppresses the phosphatase activity of the calmodulin–CnA–CnB complex, resulting in the inhibition of the transcription factor calcineurin-responsive zinc finger 1 (Crz1) and corresponding stress-related genes. Subsequently, calcineurin inhibitors, like tacrolimus, may function as potent antifungals and may reverse resistance against standard antifungal drugs or increase their efficacy [108,109]. Notably, in vitro antifungal efficacy of FK506 towards planktonic cells and biofilm of Aspergillus spp. have been investigated, showing variable susceptibility [45,47,48]. Among the Aspergillus spp., most of the examined A. fumigatus and A. terreus isolates displayed MECs of 0.025–0.05 μg/mL. FK506 was especially effective against A. niger (0.006–0.012 μg/mL), reaching >90% growth inhibition. However, A. flavus isolates tended to have higher MECs (0.1–0.2 μg/mL), and no substantial impact of FK506 was recognized against A. ustus or A. versicolor [49]. Combinations of tacrolimus with voriconazole or AMB show synergistic inhibitory activity against Aspergillus spp. biofilms [47]. Furthermore, there is an in vitro fungicidal synergism between FK506 and the normally fungistatic caspofungin against A. fumigatus, resulting in delayed filamentation and the production of even smaller hyphae [110]. In vivo, FK506 showed improved survival rates in an invasive aspergillosis CD-1 mouse model (1 mg/kg of body weight/day), compared to those treated with cyclosporin A. Nevertheless, higher doses of FK506 (10 mg/kg of body weight/day) resulted in a significant decrease in survival rates. It is suggested that higher doses of FK506 trigger an immunosuppressive effect, thereby offsetting the drug’s moderate anti-aspergillosis activity [111]. Calcineurin inhibitors, such as FK506 and cyclosporine A, decrease the immune response by suppressing T cell proliferation such as interferon gamma (IFNγ) [111,112], thereby increasing overall survival rate [111]. Since IFNγ plays a role in invasive aspergillosis [112], administration of FK506 and cyclosporine A may decrease the risk of serious Aspergillus infections and provide a better protection in transplant individuals [50]. Patients under immunosuppressant therapy are at a higher risk of acquiring invasive aspergillosis. Therefore, it is essential to determine the optimal dose for the co-administration of immunosuppressants and antifungal drugs in these patients. 4.1.2. Cyclosporin A Cyclosporins, a family of lipophilic cyclic undecapeptides metabolites, are produced by the filamentous fungi, Trichoderma polysporum. Cyclosporin A, the main representative of the Cyclosporin family, is a calcineurin inhibitor with a potent immunosuppressive and antifungal activity, either on its own or in combination with existing antifungals [113,114]. Cyclosporin, in combination with the antifungals caspofungin or itraconazole, showed in vitro synergy against A. fumigatus [114]. Since calcineurin inhibitors pose immunosuppressive effects, Hsp90 inhibitors might provide more beneficial strategies. 4.1.3. Geldanamycin Geldanamycin is a member of the ansamycin antibiotic family with anti-tumor activity [51]. Geldanamycin acts as an Hsp90 inhibitor by preventing the chaperone activity of the Hsp90 by competing for ATP binding [115]. Hsp90 accelerates the development of drug resistance by triggering new mutations that have immediate phenotypic consequences. Abrogation of resistance in fungi by Hsp90 inhibitors has been suggested as a new therapeutic strategy [101]. The Hsp90 inhibitor geldanamycin and its derivatives, 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), display modest in vitro activity against molds, with an MEC ≥50% range of 0.015–16 μg/mL [49]. Nevertheless, the combination of geldanamycin with caspofungin in A. fumigatus results in fungicidal activity, as well as in azole-resistant strains [110]. Moreover, combination therapy of geldanamycin and caspofungin in the Galleria mellonella model has enhanced the survival rate of larvae with A. fumigatus infections [105]. Prior to this study, A. fumigatus has been shown to be lethal in larvae, despite monotherapy with each agent, including azole-resistant strains [105]. It has also been shown that geldanamycin enhances the efficacy of caspofungin against A. fumigatus and A. terreus by the synergistic effect [116]. 4.1.4. Trichostatin A Hindering HDACs in pathogenic fungi establishes a promising therapeutic strategy. It was showcased in A. nidulans, A. oryzae, and A. fumigatusas as an epigenetic therapy via the modified expression of related genes of virulence or drug resistance, by regulating chromatin structure and transcription through lysine deacetylation of histones [103]. HDACs eliminate acetyl groups from lysines on core histones and other cellular proteins that are involved in gene regulation of stress responses [103]. HDACs have been associated with virulence, expression and regulation of essential drug resistance-related proteins, such as the chaperone Hsp90 protein and drug efflux pumps [52,53]. Trichostatin A, a broad spectrum HDAC inhibitor, exhibits variable antifungal activity against clinical isolates of Aspergillus spp., including azole-resistant A. ustus [106]. In vitro, trichostatin A has shown weak activity against A. fumigatus and A. flavus isolates, but had better activity against 90% of A. niger, A. terreus, A. versicolor and A. ustus isolates with an MEC of 2 μg/mL [106]. Concerning antifungal interactions, synergistic activity between trichostatin A and caspofungin was observed against some Aspergillus spp. [49,117]. 4.1.5. MGCD290 MGCD290 is another selective HDAC inhibitor, which shows a high MIC (8 to >32 μg/mL) against molds, including Aspergillus spp. However, it acts synergistically with azoles (voriconazole and posaconazole) against azole-resistant fungal isolates [118]. 4.2. Ras and Sphingolipid Synthesis Pathways In C. neoformans, it has been shown that two signaling pathways of Ras and sphingolipid synthesis are necessary for the efficient propagation of infections [119,120]. Concerning the role of these pathways in virulence and structural differences of these molecules in mammalian and fungal cells, blocking the synthesis and/or function of these pathways has emerged as possible a unique target for the development of new drugs. Sphingolipids, a major class of eukaryotic lipids, present a variety of roles in fungal cellular metabolisms, heat stress response, signal transduction and virulence [62,121,122]. Various studies in Candida and Aspergillus spp. have recently shown that plasma membrane sphingolipids, such as inositol phosphoryl ceramide and glucosylceramide, have essential roles in fungal pathogenesis and drug resistance [63,64,123,124]. Targeting the enzymes involved in the sphingolipid biosynthetic pathways via inhibition or gene deletion can potentially reduce the virulence of fungal pathogens, including Aspergillus spp. [62,122]. Several new sphingolipid inhibitors have been discovered, which reduce the levels of fungal sphingolipids in contrast with mammalian cells such as Aureobasidin A, d-threo-1-phenyl-2-palmitoyl-3-pyrrolidinopropanol, d-threo-3′,4′-ethylenedioxy-P4), N′-(3-bromo-4-hydroxybenzylidene)-2-methyl benzohydrazide and 3-bromo-N′-(3-bromo-4-hydroxybenzylidene) benzohydrazide) [65,124,125,126]. The Ras family are a cluster of membrane-associated guanosine triphosphatase (GTPase) proteins that play a major role in signal transduction pathways in eukaryotic cells. Ras proteins are stimulated by binding to guanosine nucleotide exchange factors (GEFs) and are inactivated by interaction with GTPase activator proteins (GAPs) [127]. Mature Ras proteins could be transported to the plasma membrane via two pathways, either through trafficking by the secretory system in their palmitoylated form or being non-palmitoylated by a non-classical pathway [128]. It has been described that a lack of Ras signaling pathways in A. fumigatus through palmitoylation-driven inhibition, results in decreased fungal growth, decreased cell wall integrity, and loss of virulence [129,130]. Ras signaling pathways have been investigated extensively for developing anticancer therapeutics. Since the mechanisms of Ras activation and post-translational modifications are common in both humans and fungi, this information could be translated into novel strategies in treating Aspergillus infections. Several antifungal targets within the Ras signaling pathway could be of interest, including a) hindering Ras Proteins and their interactions [131], b) inhibition of Ras post-translational modifications such as farnesylation, and [132] c) inhibition of palmitoylation [133]. Therefore, designing or discovering inhibitors with high selectivity to fungal homologs could be a promising therapeutic approach. 4.3. Trehalose Synthesis Pathway Trehalose, a non-reducing disaccharide, acts as a reserve carbohydrate source in cell processes such as glycolysis, sporulation, and germination in fungal spores and vegetative cells, including A. niger, S. cerevisiae, and Neurospora crassa [134]. It functions as a protectant under environmental stress and nutrient limitation [135], maintaining the cell membrane under stressful conditions by interacting with proteins and phospholipids. Therefore, the structure of the membrane under dehydrated conditions and thermal-related stress is preserved [136]. Trehalose biosynthesis is one of the pathways that exist in fungi, including C. albicans, C. neoformans, and A. fumigatus but not in humans, rendering it a promising target for novel antifungal agents [135]. The main characteristics of this pathway are its direct link to glycolysis [137] and the participation of two primary synthesizing enzymes, trehalose-6-phosphate synthase (Tps1), and trehalose-6-phosphate phosphatase (Tps2), which are specific to this path [138]. Several investigations have focused on the trehalose pathway in Aspergillus spp. [139,140,141,142], confirming the critical role of this biosynthesis pathway in development, stress response, and pathogenicity. In A. fumigatus, the enhanced trehalose content of hyphae is associated with response to heat shock stress, which is correlated with increased expression levels of two putative trehalose-6-phosphate synthase genes, tpsA, and tpsB. It has also been demonstrated that blocking this pathway affects conidial germination, thermo-tolerance, and response to high-level oxidative stress in vitro. Interestingly, mutant strains of tpsA and tpsB resulted in more virulence in a murine model of invasive aspergillosis [141]. Compared to compounds targeting Ras and calcineurin pathways, few inhibitors have been discovered for this pathway, which makes it an attractive potential target of antifungal therapy with few consequences on mammal metabolism and biochemical networks. 4.4. High-Osmolarity Glycerol (HOG)-Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway In S. cerevisiae, the HOG-MAPK signaling pathway controls the adaptation to environmental stress and regulation of fungal morphology [143]. The HOG-MAPK pathway consists of two cascades of signaling proteins, the putative membrane protein and the two-component phosphorelay system [144]. Diverse extracellular stimuli activate MAPK cascades through subsequent phosphorylation and MAPK activation, resulting in the activation of transcription factors and the expression of distinct genes [145]. However, the function of the HOG-MAPK pathway in filamentous fungi remains unclear. In A. fumigatus, the contribution of the HOG-MAPK pathway has been discovered to influence adaption to thermal stress and susceptibility to itraconazole at high temperature [146]. Further studies showcased that the lack of MAPK in A. fumigatus enhanced the sensitivity to oxidative stress induced antifungals, including amphotericin B and itraconazole [147]. The absence of two-component phosphorelay systems of MAPK in humans may provide suitable targets for developing new fungicides without notable toxicity [148]. The HOG pathway has been recognized as the target for fludioxonil, phenylpyrrole fungicide with a broad spectrum, providing insight into novel targets for synergistic antifungal drug combinations [149,150]. It is thought to act by interfering with sugar transport and sugar phosphorylation and by disordering the membrane [151]. The above-mentioned pathways are examples of potential antifungal targets that provide a framework for the development of antifungal compounds. 5. Natural Products as Anti-Aspergillus Agents Natural products have been important as a source of bioactive molecules, including potent antifungals [152]. Amphotericin B and caspofungin have been derived from natural sources [153], and several investigations have focused on the screening of natural extracts with antifungal activities [154,155]. Rosemary essential oil (REO) demonstrated in vitro activity against A. flavous, with an MIC and minimum fungicidal concentrations (MFC) of 500 µg/mL. Further investigations confirmed changes in fungal morphology and a reduction in ergosterol content, suggesting REO as a potent compound [155]. Moreover, antifungal activity of 82 essential oils against A. niger, C. albicans, and C. neoformans has been investigated [156]. A. niger showed weak susceptibility, and 45% of essential oils displayed activity against C. neoformans isolates. Humidimycin, a bacterial ring peptide, has been shown to potentiate the activity of sub-lethal concentrations of caspofungin against A. fumigatus isolates [157]. Humidimycin is thought to be involved in HOG pathway inhibition, thereby decreasing the protective stress response induced by caspofungin [157]. Since the HOG pathway has not been found in mammals, humidimycin is a promising compound for further analysis. 6. Perspective Given the rise of antifungal drug resistance, novel antifungal agents and new drug targets are highly needed. Recently, an expanding insight into the fungal cellular structures and related processes has contributed to the development of promising antifungal drugs with a wide therapeutic index and potentially without targeting human cells. Novel compounds with a broad-spectrum of antifungal activity may overcome the lack of sensitive diagnostic assays and may target drug-resistant representatives. The feasibility and results from ongoing clinical trials are highly awaited. Author Contributions R.V.-S. and C.L.-F. wrote this article. All authors have read and agreed to the published version of the manuscript. Funding W1253-B24 doctoral program HOROS. Open Access Funding by the Austrian Science Fund (FWF). Conflicts of Interest The authors declare no conflict of interest. The figure has been created by BioRender.com. Abbreviations IFI Invasive fungal infection MICs Minimum inhibitory concentrations MEC Minimum effective concentration GM Geometric mean GPI Glycosylphosphatidylinositol DHODH Dihydroorotate dehydrogenase HDACs Histone deacetylases GAPs GTPase activator proteins GEFs Guanosine nucleotide exchange factors HOG High osmolarity glycerol MAPK Mitogen activated protein kinase REO Rosemary essential oil MFC Minimum fungicidal activity IFNγ Interferon gamma Crz1 Calcineurin-responsive Zinc finger 1 Gwt1 GPI-anchored wall transferase 1 GTPase Guanosine Triphosphatase Figure 1 Target sites and potential pathways of the novel antifungals. This diagram of a fungal cell indicates various molecules that can be tackled by antifungal agents (blue boxes), including cell wall, cell membrane, and also intracellular targets such as mitochondria and processes like metabolisms and stress responses. jof-06-00213-t001_Table 1Table 1 Summary of antifungal compounds mentioned in the review. Class Antifungal Compound Mechanism of Action In Vitro Activity (Minimum inhibitory concentration) (MIC) Advantage Clinical Trial Phase References Arylamidine T-2307 Inhibits intracellular mitochondrial membrane respiration potential 0.0156–2 μg/mL A.fumigatus, A. terreus, A. flavus, A. nidulans and A. niger ◦ Preferential uptake by fungal cells Phase I [20,21,22] Glycosylphosphatidylinositol (GPI) inhibitors E1210/APX001 (Fosmanogepix) Inhibition of Gwt1, Glycosylphosphatidylinositol (GPI) anchor protein synthesis ≤0.008-0.25 μg/mL A.fumigatus, A. terreus, A. flavus and A. niger ◦ Broad spectrum ◦ Fungal-specific target ◦ Synergizes with available antifungal Phase II planned [23,24,25] Siderophore VL-2397 (ASP2397) Uptaking by specific siderophore iron transporter (Sit1), but an unknown intracellular target 1-4 μg/mL A.fumigatus, A. terreus, A. flavus and A. niger Phase II [26,27,28] Orotomides F90138 (olorofim) Inhibition of dihydroorotate dehydrogenase (DHODH) in pyrimidine synthesis <0.03 µg/mL A.fumigatus, azole-resistant A. fumigatus, A. terreus, A. flavus and A. nidulans ◦ Oral and intravenous formulation ◦ No reported cross-resistance Phase III [29,30,31,32] Tetrazole VT-1598 Inhibition lanosterol demethylase 0.25-2 μg/mL A. fumigatus ◦ Selectivity for fungal CYP51 ◦ Broad spectrum Phase I [33,34] Polyenes Amphotericin B (AMB) New formulations Fungal membrane disruption or Pore formation by binding to ergosterol 0.25–1 μg/mL A. fumigatus 1–8 μg/mL A. fumigatus ◦ Broad spectrum ◦ Oral administration ◦ Less toxicity Phase II No human clinical trials [35,36] [37,38,39] [40,41,42,43,44] Coch-AmB AMB-conjugated with polysaccharides Calcineurin inhibitors Tacrolimus (FK506) Calcineurin Inhibition 0.01–0.6 μg/mL (Minimum effective concentration) (MEC)A. fumigatus ◦ Synergizes with caspofungin No human clinical trials [45,46,47,48,49,50] Calcineurin inhibitors Cyclosporin A Calcineurin Inhibition 0.5–1 μg/mL (MEC) A. fumigatus No human clinical trials [50] Hsp90 inhibitors Geldanamycin Heat shock protein 90 (Hsp90) Inhibition 4 μg/mL (MEC) A. fumigatus ◦ Synergizes with caspofungin No human clinical trials [51] HDAC inhibitors Trichostatin A Histone deacetylase (HDAC) Inhibition 4 μg/mL A. fumigatus ◦ Synergizes with caspofungin No human clinical trials [52] HDAC inhibitors MGCD290 Histone deacetylase (HDAC) Inhibition 8->32 μg/mL A. fumigatus ◦ Broad spectrum ◦ Synergizes with approved antifungal Phase II [53] Glucan synthesis inhibitors CD101 (Biafungin) 1,3-β-d-glucan synthase Inhibition ≤0.008/0.03 μg/mL A. fumigatus, A. terreus, A. flavus and A. niger ◦ Improved stability ◦ Long half-life ◦ Safety profile Phase III [54,55,56,57,58] Glucan synthesis inhibitors SCY-078 (MK-3118) 1,3-β-d-glucan synthase Inhibition 0.03-0.25 µg/mL A.fumigatus, A. terreus, A. flavus and A. niger ◦ Oral and IV formulation ◦ Activity against itraconazole-resistant Aspergillus strains Phase III [59,60,61] Glycolipid inhibitors Aureobasidin A Inhibition of inositol phosphorylceramide (IPC) synthase, sphingolipid syntheses 4 μg/mL A. fumigatus ◦ Synergize with caspofungin No human clinical trials [62,63,64,65] ==== Refs References 1. Bongomin F. Gago S. Oladele R.O. Denning D.W. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision J. Fungi (Basel) 2017 3 57 10.3390/jof3040057 29371573 2. Brown G. Denning D. Gow N. Levitz S. Netea M. White T. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 165rv13 10.1126/scitranslmed.3004404 23253612 3. Richardson M. Changing patterns and trends in systemic fungal infections J. Antimicrob. Chemother. 2005 56 i5 i11 10.1093/jac/dki218 16120635 4. Lass-Flörl C. Aigner M. Nachbaur D. Eschertzhuber S. Bucher B. Geltner C. Bellmann R. Lackner M. Orth-Höller D. Würzner R. Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: A 12-year experience Infection 2017 45 867 875 10.1007/s15010-017-1072-6 28956284 5. Lass- Flörl C. Diagnosing fungal infections in haematology patients—Another case of less is more in the clinical setting? Clin. Microbiol. Infect. 2017 23 896 897 10.1016/j.cmi.2017.05.022 28583740 6. Kontoyiannis D. Marr K. Park B. Alexander B. Anaissie E. Walsh T. Ito J. Andes D. Baddley J. Brown J. Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001–2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database Clin. Infect. Dis. 2010 50 1091 1100 10.1086/651263 20218877 7. Posteraro B. Torelli R. De Carolis E. Posteraro P. Sanguinetti M. Update on the laboratory diagnosis of invasive fungal infections Mediterr. J. Hematol. Infect. Dis. 2011 3 e2011002 10.4084/mjhid.2011.002 21625306 8. Kullberg B.J. Oude Lashof A.M. Epidemiology of opportunistic invasive mycoses Eur. J. Med. Res. 2002 7 183 191 12069910 9. Sugui J. Kwon-Chung K. Juvvadi P. Latge J. Steinbach W. Aspergillus fumigatus and related species Csh. Perspect. Med. 2014 5 a019786 10.1101/cshperspect.a019786 10. Walsh T. Anaissie E. Denning D. Herbrecht R. Kontoyiannis D. Marr K. Morrison V. Segal B. Steinbach W. Stevens D. Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America Clin. Infect. Dis. 2008 46 327 360 10.1086/525258 18177225 11. Mayr A. Lass-Flörl C. Epidemiology and antifungal resistance in invasive aspergillosis according to primary disease - review of the literature Eur. J. Med. Res. 2011 16 153 10.1186/2047-783X-16-4-153 21486729 12. Erjavec Z. Kluin-Nelemans H. Verweij P. Trends in invasive fungal infections, with emphasis on invasive aspergillosis Clin. Microbiol. Infect. 2009 15 625 633 10.1111/j.1469-0691.2009.02929.x 19673973 13. Roemer T. Krysan D. Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches Cold Spring Harbor Perspect. Med. 2014 4 a019703 10.1101/cshperspect.a019703 24789878 14. Gintjee T. Donnelley M. Thompson G. Aspiring antifungals: Review of current antifungal pipeline developments J. Fungi (Basel) 2020 6 28 10.3390/jof6010028 15. Patterson T. Thompson G. Denning D. Fishman J. Hadley S. Herbrecht R. Kontoyiannis D. Marr K. Morrison V. Nguyen M. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious disease’s society of America Clin. Infect. Dis. 2016 63 e1 e60 10.1093/cid/ciw326 27365388 16. Lass-Flörl C. Triazole antifungal agents in invasive fungal infections Drugs 2011 71 2405 2419 10.2165/11596540-000000000-00000 22141384 17. Aigner M. Lass-Flörl C. Treatment of drug-resistant Aspergillus infection Expert Opin. Pharmacol. 2015 16 2267 2270 10.1517/14656566.2015.1083976 26328502 18. Zoran T. Sartori B. Sappl L. Aigner M. Sánchez-Reus F. Rezusta A. Chowdhary A. Taj-Aldeen S. Arendrup M. Oliveri S. Azole-resistance in Aspergillus terreus and related species: An emerging problem or a rare phenomenon? Front. Microbiol. 2018 9 516 10.3389/fmicb.2018.00516 29643840 19. Gonçalves S. Souza A. Chowdhary A. Meis J. Colombo A. Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus Mycoses 2016 59 198 219 10.1111/myc.12469 26810669 20. Mitsuyama J. Nomura N. Hashimoto K. Yamada E. Nishikawa H. Kaeriyama M. Kimura A. Todo Y. Narita H. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine Antimicrob. Agents. Chemother. 2008 52 1318 1324 10.1128/AAC.01159-07 18227186 21. Nishikawa H. Sakagami T. Yamada E. Fukuda Y. Hayakawa H. Nomura N. Mitsuyama J. Miyazaki T. Mukae H. Kohno S. T-2307, a novel arylamidine, is transported into Candida albicans by a high-affinity spermine and spermidine carrier regulated by Agp2 Antimicrob. Agents. Chemother. 2016 71 1845 1855 10.1093/jac/dkw095 27090633 22. Nishikawa H. Yamada E. Shibata T. Uchihashi S. Fan H. Hayakawa H. Nomura N. Mitsuyama J. Uptake of T-2307, a novel arylamidine, in Candida albicans Antimicrob. Agents. Chemother. 2010 65 1681 1687 10.1093/jac/dkq177 20513704 23. Hata K. Horii T. Miyazaki M. Watanabe N. Okubo M. Sonoda J. Nakamoto K. Tanaka K. Shirotori S. Murai N. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis Antimicrob. Agents. Chemother. 2011 55 4543 4551 10.1128/AAC.00366-11 21788462 24. Miyazaki M. Horii T. Hata K. Watanabe N. Nakamoto K. Tanaka K. Shirotori S. Murai N. Inoue S. Matsukura M. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds Antimicrob. Agents. Chemother. 2011 55 4652 4658 10.1128/AAC.00291-11 21825291 25. Watanabe N. Miyazaki M. Horii T. Sagane K. Tsukahara K. Hata K. E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis Antimicrob. Agents. Chemother. 2011 56 960 971 10.1128/AAC.00731-11 22143530 26. Nakamura I. Yoshimura S. Masaki T. Takase S. Ohsumi K. Hashimoto M. Furukawa S. Fujie A. ASP2397: A novel antifungal agent produced by Acremonium persicinum MF-347833 J. Antibiot. Res. 2016 70 45 51 10.1038/ja.2016.107 27. Nakamura I. Ohsumi K. Takeda S. Katsumata K. Matsumoto S. Akamatsu S. Mitori H. Nakai T. ASP2397 Is a novel natural compound that exhibits rapid and potent fungicidal activity against Aspergillus species through a specific transporter Antimicrob. Agents Chemother. 2019 63 e02689-18 10.1128/AAC.02689-18 31405853 28. Arendrup M. Jensen R. Cuenca-Estrella M. In vitro activity of ASP2397 against Aspergillus isolates with or without acquired azole resistance mechanisms Antimicrob. Agents Chemother. 2015 60 532 536 10.1128/AAC.02336-15 26552973 29. Oliver J. Sibley G. Beckmann N. Dobb K. Slater M. McEntee L. du Pré S. Livermore J. Bromley M. Wiederhold N. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase Proc. Natl. Acad. Sci. USA 2016 113 12809 12814 10.1073/pnas.1608304113 27791100 30. Lackner M. Birch M. Naschberger V. Grässle D. Beckmann N. Warn P. Gould J. Law D. Lass-Flörl C. Binder U. Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei J. Antimicrob. Chemother. 2018 73 3068 3073 10.1093/jac/dky329 30351438 31. Buil J. Rijs A. Meis J. Birch M. Law D. Melchers W. Verweij P. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates J. Antimicrob. Chemother. 2017 72 2548 2552 10.1093/jac/dkx177 28605488 32. Negri C. Johnson A. McEntee L. Box H. Whalley S. Schwartz J. Ramos-Martín V. Livermore J. Kolamunnage-Dona R. Colombo A. pharmacodynamics of the novel antifungal agent F901318 for acute sinopulmonary aspergillosis caused by Aspergillus flavus J. Infect. Dis. 2017 217 1118 1127 10.1093/infdis/jix479 28968675 33. Hoekstra W. Garvey E. Moore W. Rafferty S. Yates C. Schotzinger R. Design and optimization of highly-selective fungal CYP51 inhibitors Bioorg. Med. Chem. Lett. 2014 24 3455 3458 10.1016/j.bmcl.2014.05.068 24948565 34. Wiederhold N. Patterson H. Tran B. Yates C. Schotzinger R. Garvey E. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus J. Antimicrob. Chemother. 2017 73 404 408 10.1093/jac/dkx410 29190379 35. Mesa-Arango A. Scorzoni L. Zaragoza O. It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug Front. Microbiol. 2012 3 1 10 10.3389/fmicb.2012.00286 22275914 36. Vahedi Shahandashti R. Lass-Flörl C. Antifungal resistance in Aspergillus terreus : A current scenario Fungal Genet. Biol. 2019 131 103247 10.1016/j.fgb.2019.103247 31247322 37. Janout V. Schell W. Thévenin D. Yu Y. Perfect J. Regen S. Taming amphotericin B Bioconjugate Chem. 2015 26 2021 2024 10.1021/acs.bioconjchem.5b00463 38. Gallis H. Drew R. Pickard W. Amphotericin B: 30 years of clinical experience Clin. Infect. Dis. 1990 12 308 329 10.1093/clinids/12.2.308 39. Santangelo R. Paderu P. Delmas G. Chen Z. Mannino R. Zarif L. Perlin D. Efficacy of oral aochleate-amphotericin B in a mouse model of systemic candidiasis Antimicrob. Agents Chemother. 2000 44 2356 2360 10.1128/AAC.44.9.2356-2360.2000 10952579 40. Janout V. Bienvenu C. Schell W. Perfect J. Regen S. Molecular Umbrella–Amphotericin B conjugates Bioconjugate Chem. 2014 25 1408 1411 10.1021/bc500277v 41. Yang Z. Liu M. Chen J. Fang W. Zhang Y. Yuan M. Gao J. Development and characterization of amphotericin B nanosuspensions for oral administration through a simple top-down method Curr. Pharm. Biotechno. 2014 15 569 576 10.2174/1389201015666140706160709 42. Halperin A. Shadkchan Y. Pisarevsky E. Szpilman A. Sandovsky H. Osherov N. Benhar I. Novel water-soluble amphotericin B-PEG conjugates with low toxicity and potent in vivo efficacy J. Med. Chem. 2016 59 1197 1206 10.1021/acs.jmedchem.5b01862 26816333 43. Ickowicz D. Farber S. Sionov E. Kagan S. Hoffman A. Polacheck I. Domb A. Activity, reduced toxicity, and scale-up synthesis of amphotericin B-conjugated polysaccharide Biomacromolecules 2014 15 2079 2089 10.1021/bm5002125 24779556 44. Vyas S. Gupta S. Optimizing efficacy of amphotericin B through nanomodification Int. J. Nanomed. 2006 1 417 432 10.2147/nano.2006.1.4.417 17722276 45. Juvvadi P. Lee S. Heitman J. Steinbach W. Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach Virulence 2016 8 186 197 10.1080/21505594.2016.1201250 27325145 46. Juvvadi P. Lamoth F. Steinbach W. Calcineurin as a multifunctional regulator: Unraveling novel functions in fungal stress responses, hyphal growth, drug resistance, and pathogenesis Fungal Biol. Rev. 2014 28 56 69 10.1016/j.fbr.2014.02.004 25383089 47. Gao L. Sun Y. In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms Antimicrob. Agents Chemother. 2015 59 7097 7099 10.1128/AAC.01510-15 26303797 48. Lee Y. Lee K. Lee S. Beom J. Hwangbo A. Jung J. Song M. Yoo Y. Kang S. Averette A. In vitro and in vivo assessment of FK506 analogs as novel antifungal drug candidates Antimicrob. Agents Chemother. 2018 62 10.1128/AAC.01627-18 49. Lamoth F. Alexander B. Juvvadi P. Steinbach W. Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species J. Antimicrob. Chemother. 2015 70 1408 1411 10.1093/jac/dku549 25558076 50. High K.P. The antimicrobial activities of cyclosporine, FK506, and rapamycin Transplantation 1994 27 1689 1700 10.1097/00007890-199457120-00001 7517076 51. Ochel H. Eichhorn K. Gademann G. Geldanamycin: The prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones Cell Stress Chaperones 2001 6 105 10.1379/1466-1268(2001)006<0105:GTPOAC>2.0.CO;2 11599571 52. Robbins N. Leach M. Cowen L. Lysine deacetylases Hda1 and Rpd3 regulate Hsp90 function thereby governing fungal drug resistance Cell Rep. 2012 2 878 888 10.1016/j.celrep.2012.08.035 23041319 53. Wurtele H. Tsao S. Lépine G. Mullick A. Tremblay J. Drogaris P. Lee E. Thibault P. Verreault A. Raymond M. Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy Nat. Med. 2010 16 774 780 10.1038/nm.2175 20601951 54. Krishnan B. James K. Polowy K. Bryant B. Vaidya A. Smith S. Laudeman C. CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility J. Antibiot. 2016 70 130 135 10.1038/ja.2016.89 27507631 55. Shields R. Nguyen M. Press E. Kwa A. Cheng S. Du C. Clancy C. The presence of an FKS mutation rather than mic is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata Antimicrob. Agents Chemother. 2012 56 4862 4869 10.1128/AAC.00027-12 22751546 56. Ong V. Hough G. Schlosser M. Bartizal K. Balkovec J. James K. Krishnan B. Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel Echinocandin Antimicrob. Agents Chemother. 2016 60 6872 6879 10.1128/AAC.00701-16 27620474 57. Sandison T. De Anda C. Fang E. Das A. Prokocimer P. Clinical response of Tedizolid versus Linezolid in acute bacterial skin and skin structure infections by severity measure using a pooled analysis from two phase 3 double-blind trials Antimicrob. Agents Chemother. 2017 61 10.1128/AAC.02687-16 58. Pfaller M. Messer S. Rhomberg P. Jones R. Castanheira M. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates J. Antimicrob. Chemother. 2016 71 2868 2873 10.1093/jac/dkw214 27287236 59. Walker S. Xu Y. Triantafyllou I. Waldman M. Mendrick C. Brown N. Mann P. Chau A. Patel R. Bauman N. Discovery of a novel class of orally active antifungal β-1,3-d-glucan synthase inhibitors Antimicrob. Agents Chemother. 2011 55 5099 5106 10.1128/AAC.00432-11 21844320 60. Pfaller M. Messer S. Motyl M. Jones R. Castanheira M. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods Antimicrob. Agents Chemother. 2012 57 1065 1068 10.1128/AAC.01588-12 23229479 61. Jiménez-Ortigosa C. Paderu P. Motyl M. Perlin D. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus Species Isolates Antimicrob. Agents Chemother. 2013 58 1248 1251 10.1128/AAC.02145-13 24323472 62. Obeid L. Okamoto Y. Mao C. Yeast sphingolipids: Metabolism and biology BBA-Mol. Cell. Biol. L 2002 1585 163 171 10.1016/S1388-1981(02)00337-2 63. Rella A. Farnoud A. Del Poeta M. Plasma membrane lipids and their role in fungal virulence Prog. Lipid Res. 2016 61 63 72 10.1016/j.plipres.2015.11.003 26703191 64. Ruiz-Herrera J. Victoria Elorza M. Valentà n E. Sentandreu R. Molecular organization of the cell wall of Candida albicans and its relation to pathogenicity FEMS Yeast Res. 2005 6 14 29 10.1111/j.1567-1364.2005.00017.x 16423067 65. Rollin-Pinheiro R. Singh A. Barreto-Bergter E. Del Poeta M. Sphingolipids as targets for treatment of fungal infections Future Med. Chem. 2016 8 1469 1484 10.4155/fmc-2016-0053 27502288 66. Miesel L. Lin K.Y. Ong V. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy Pharmacol. Res. Perspect. 2019 7 e00546 10.1002/prp2.546 31763045 67. Jiménez-Ortigosa C. Moore C. Denning D. Perlin D. Emergence of echinocandin resistance due to a point mutation in the fks1 gene of Aspergillus fumigatus in a patient with chronic pulmonary aspergillosis Antimicrob. Agents Chemother. 2017 61 10.1128/AAC.01277-17 68. Rocha E. Garcia-Effron G. Park S. Perlin D. A ser678pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus Antimicrob. Agents Chemother. 2007 51 4174 4176 10.1128/AAC.00917-07 17724146 69. Satish S. Perlin D. Echinocandin resistance in Aspergillus fumigatus has broad implications for membrane lipid perturbations that influence drug-target interactions Microbiol. Insights 2019 12 1 4 10.1177/1178636119897034 70. Borroto-Esoda K. Barat S. Angulo D. Holden K. Warn P. SCY-078 Demonstrates significant antifungal activity in a murine model of invasive aspergillosis Open Forum Infect Dis. 2017 4 S472 10.1093/ofid/ofx163.1207 71. Delmas G. Park S. Chen Z. Tan F. Kashiwazaki R. Zarif L. Perlin D. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis Antimicrob. Agents Chemother. 2002 46 2704 2707 10.1128/AAC.46.8.2704-2707.2002 12121962 72. Yamada E. Nishikawa H. Nomura N. Mitsuyama J. T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena Antimicrob. Agents. Chemother. 2010 54 3630 3634 10.1128/AAC.00355-10 20547803 73. Wiederhold N. Najvar L. Fothergill A. Bocanegra R. Olivo M. McCarthy D. Kirkpatrick W. Fukuda Y. Mitsuyama J. Patterson T. The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans Antimicrob. Agents. Chemother. 2014 59 1341 1343 10.1128/AAC.04228-14 25451054 74. Hodges M. Ople E. Shaw K. Mansbach R. van Marle S.S. van Hoogdalem E. Kramer W. Wedel P. Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability IDweek San Diego, CA, USA 2017 75. Samalova M. Carr P. Bromley M. Blatzer M. Moya-Nilges M. Latgé J. Mouyna I. GPI anchored proteins in Aspergillus fumigatus and cell wall morphogenesis Curr. Top. Microbiol. Immunol. 2020 167 186 10.1007/82_2020_207 32418035 76. Tsukahara K. Hata K. Nakamoto K. Sagane K. Watanabe N. Kuromitsu J. Kai J. Tsuchiya M. Ohba F. Jigami Y. Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly Mol. Microbiol. 2003 48 1029 1042 10.1046/j.1365-2958.2003.03481.x 12753194 77. Umemura M. Okamoto M. Nakayama K. Sagane K. Tsukahara K. Hata K. Jigami Y. GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast J. Biol. Chem. 2003 278 23639 23647 10.1074/jbc.M301044200 12714589 78. Mansbach R. Shaw K. Hodges M. Coleman S. Fitzsimmons M. Absorption, Distribution, and excretion of 14c-apx001 after single-dose administration to rats and monkeys Open Forum Infect. Dis. 2017 4 S472 10.1093/ofid/ofx163.1209 79. Mammen M. Armas D. Hughes F. Hopkins A. Fisher C. Resch P. Rusalov D. Sullivan S. Smith L. First-in-human phase 1 study to assess safety, tolerability, and pharmacokinetics of a novel antifungal drug, VL-2397, in healthy adults Antimicrob. Agents Chemother. 2019 63 e00969-19 10.1128/AAC.00969-19 31427299 80. Vical Pharmaceutics Development of VL-2397 as an Antifungal Drug Candidate to Treat Invasive Fungal Infections Available online: http://s1.q4cdn.com/508380786/files/doc_downloads/VL2397_ASM_Microbe_2017/Sullivan_ASM_Microbe_2017_Oral_Presentation.pdf (accessed on 27 July 2019) 81. ClinicalTrials.gov. VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults Available online: https://clinicaltrials.gov/ct2/show/NCT03327727 (accessed on 27 July 2019) 82. Haas H. Eisendle M. Turgeon B. Siderophores in fungal physiology and virulence Annu. Rev. Phytopathol. 2008 46 149 187 10.1146/annurev.phyto.45.062806.094338 18680426 83. Neilands J. Siderophores: Structure and function of microbial iron transport compounds J. Biol. Chem. 1995 270 26723 26726 10.1074/jbc.270.45.26723 7592901 84. Yun C. Ferea T. Rashford J. Ardon O. Brown P. Botstein D. Kaplan J. Philpott C. Desferrioxamine-mediated iron uptake in Saccharomyces cerevisiae J. Biol. Chem. 2000 275 10709 10715 10.1074/jbc.275.14.10709 10744769 85. Nakamura I. Ohsumi K. Yoshikawa K. Kanasaki R. Masaki T. Takase S. Hashimoto M. Fujie A. Nakai T. Matsumoto S. ASP2397: A novel natural product with potent fungicidal activity against Aspergillus spp. (1)—A new mode of action and in vitro activity Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Washington, DC, USA 17–21 September 2014 86. Fisher M. Hawkins N. Sanglard D. Gurr S. Worldwide emergence of resistance to antifungal drugs challenges human health and food security Science 2018 360 739 742 10.1126/science.aap7999 29773744 87. Seyedmousavi S. Chang Y. Law D. Birch M. Rex J. Kwon-Chung K. Efficacy of Olorofim (F901318) against Aspergillus fumigatus , A. nidulans , and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease Antimicrob. Agents Chemother. 2019 63 10.1128/AAC.00129-19 30885903 88. Francois I. Cammue B. Borgers M. Ausma J. Dispersyn G. Thevissen K. Azoles: Mode of antifungal action and resistance development. effect of miconazole on endogenous reactive oxygen species production in Candida albicans Anti-Infect. Agents Med. Chem. 2006 5 3 13 10.2174/187152106774755554 89. Yates C. Garvey E. Shaver S. Schotzinger R. Hoekstra W. Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors Bioorg. Med. Chem. Lett. 2017 27 3243 3248 10.1016/j.bmcl.2017.06.037 28651982 90. Hargrove T. Garvey E. Hoekstra W. Yates C. Wawrzak Z. Rachakonda G. Villalta F. Lepesheva G. Crystal structure of the new investigational drug candidate vt-1598 in complex with Aspergillus fumigatus sterol 14α-demethylase provides insights into its broad-spectrum antifungal activity Antimicrob. Agents Chemother. 2017 61 10.1128/AAC.00570-17 28461309 91. Garvey E. Sharp A. Warn P. Yates C. Atari M. Thomas S. Schotzinger R. The novel fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity in murine models of invasive aspergillosis Med. Mycol. J. 2019 58 505 513 10.1093/mmy/myz092 92. Muller E. Mackin N. Erdman S. Cunningham K. Fig1p facilitates Ca2+ influx and cell fusion during mating of Saccharomyces cerevisiae J. Biol. Chem. 2003 278 38461 38469 10.1074/jbc.M304089200 12878605 93. Patenaude C. Zhang Y. Cormack B. Köhler J. Rao R. Essential role for vacuolar acidification in Candida albicans virulence J. Biol. Chem. 2013 288 26256 26264 10.1074/jbc.M113.494815 23884420 94. Jia X. Wang Y. Jia Y. Gao P. Xu Y. Wang L. Cao Y. Cao Y. Zhang L. Jiang Y. RTA2 is involved in calcineurin-mediated azole resistance and sphingoid long-chain base release in Candida albicans Cell Mol. Life Sci. 2008 66 122 134 10.1007/s00018-008-8409-3 95. Edlind T. Smith L. Henry K. Katiyar S. Nickels J. Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling Mol. Microbiol. 2002 46 257 268 10.1046/j.1365-2958.2002.03165.x 12366848 96. Steinbach W. Cramer R. Perfect B. Asfaw Y. Sauer T. Najvar L. Kirkpatrick W. Patterson T. Benjamin D. Heitman J. Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus Eukaryot. Cell 2006 5 1091 1103 10.1128/EC.00139-06 16835453 97. Blankenship J. Steinbach W. Perfect J. Heitman J. Teaching old drugs new tricks: Reincarnating immunosuppressants as antifungal drugs Curr. Opin. Investig. Drugs 2003 4 192 199 12669381 98. Lamoth F. Juvvadi P. Steinbach W. Heat shock protein 90 (Hsp90): A novel antifungal target against Aspergillus fumigatus Crit. Rev. Microbiol. 2014 42 310 321 10.3109/1040841X.2014.947239 25243616 99. Pearl L. Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery Annu. Rev. Biochem. 2006 75 271 294 10.1146/annurev.biochem.75.103004.142738 16756493 100. Wandinger S. Richter K. Buchner J. The Hsp90 chaperone machinery J. Biol. Chem. 2008 283 18473 18477 10.1074/jbc.R800007200 18442971 101. Cowen L. Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi Science 2005 309 2185 2189 10.1126/science.1118370 16195452 102. Blum G. Kainzner B. Grif K. Dietrich H. Zeiger B. Sonnweber T. Lass-Flörl C. In vitro and in vivo role of heat shock protein 90 in amphotericin B resistance of Aspergillus terreus Clin. Microbiol. Infect. 2013 19 50 55 10.1111/j.1469-0691.2012.03848.x 22515428 103. Lamoth F. Juvvadi P. Steinbach W. Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis Front. Microbiol. 2015 6 96 10.3389/fmicb.2015.00096 25762988 104. Cowen L. Carpenter A. Matangkasombut O. Fink G. Lindquist S. Genetic architecture of Hsp90-dependent drug resistance Eukaryot. Cell 2006 5 2184 2188 10.1128/EC.00274-06 17056742 105. Cowen L. Singh S. Köhler J. Collins C. Zaas A. Schell W. Aziz H. Mylonakis E. Perfect J. Whitesell L. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease Proc. Natl. Acad. Sci. USA 2009 106 2818 2823 10.1073/pnas.0813394106 19196973 106. Singh S. Robbins N. Zaas A. Schell W. Perfect J. Cowen L. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin PLoS Pathog. 2009 5 e1000532 10.1371/journal.ppat.1000532 19649312 107. Kino T. Hatanaka H. Hashimoto M. Nishiyama M. Goto T. Okuhara M. Kohsaka M. Aoki H. Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces . I. Fermentation, isolation, and physico-chemical and biological characteristics J. Antibiot. 1987 40 1249 1255 10.7164/antibiotics.40.1249 2445721 108. Maesaki S. Marichal P. Hossain M. Sanglard D. Vanden Bossche H. Kohno S. Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains J. Antimicrob. Chemother. 1998 42 747 753 10.1093/jac/42.6.747 10052898 109. Uppuluri P. Nett J. Heitman J. Andes D. Synergistic Effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms Antimicrob. Agents Chemother. 2008 52 1127 1132 10.1128/AAC.01397-07 18180354 110. Steinbach W. Schell W. Blankenship J. Onyewu C. Heitman J. Perfect J. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus Antimicrob. Agents Chemother. 2004 48 1664 1669 10.1128/AAC.48.5.1664-1669.2004 15105118 111. High K. Washburn R. Invasive aspergillosis in mice immunosuppressed with cyclosporin a, tacrolimus (FK506), or sirolimus (rapamycin) J. Infect. Dis. 1997 175 222 225 10.1093/infdis/175.1.222 8985226 112. Nagai H. Guo J. Choi H. Kurup V. Interferon-and tumor necrosis factor- protect mice from invasive aspergillosis J. Infect. Dis. 1995 172 1554 1560 10.1093/infdis/172.6.1554 7594716 113. Anjum T. Iram W. Production of Cyclosporine A by Submerged Fermentation Fungal Metabol. 2015 74 372 374 114. Kontoyiannis D. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species J. Antimicrob. Chemother. 2003 51 313 316 10.1093/jac/dkg090 12562696 115. Bedin M. Gaben A. Saucier C. Mester J. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest Int. J. Cancer 2004 109 643 652 10.1002/ijc.20010 14999769 116. Lamoth F. Juvvadi P. Gehrke C. Steinbach W. In vitro activity of calcineurin and heat shock protein 90 inhibitors against Aspergillus fumigatus Azole- and Echinocandin-resistant strains Antimicrob. Agents Chemother. 2012 57 1035 1039 10.1128/AAC.01857-12 23165466 117. Lamoth F. Juvvadi P. Soderblom E. Moseley M. Asfaw Y. Steinbach W. Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus Antimicrob. Agents Chemother. 2014 58 1889 1896 10.1128/AAC.02286-13 24395240 118. Pfaller M. Messer S. Georgopapadakou N. Martell L. Besterman J. Diekema D. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens J. Clin. Microbiol. 2009 47 3797 3804 10.1128/JCM.00618-09 19794038 119. Hast M. Nichols C. Armstrong S. Kelly S. Hellinga H. Alspaugh J. Beese L. Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens J. Biol. Chem. 2011 286 35149 35162 10.1074/jbc.M111.250506 21816822 120. Mor V. Rella A. Farnoud A. Singh A. Munshi M. Bryan A. Naseem S. Konopka J. Ojima I. Bullesbach E. Identification of a new class of antifungals targeting the synthesis of fungal sphingolipids mBio 2015 6 10.1128/mBio.00647-15 121. Cheng J. Park T. Chio L. Fischl A. Ye X. Induction of apoptosis by sphingoid long-chain bases in Aspergillus nidulans Mol. Cell Biol. 2003 23 163 177 10.1128/MCB.23.1.163-177.2003 12482970 122. Dickson R. Lester R. Sphingolipid functions in Saccharomyces cerevisiae BBA-Mol. Cell. Biol. L 2002 1583 13 25 10.1016/S1388-1981(02)00210-X 123. Zhong W. Jeffries M. Georgopapadakou N. Inhibition of inositol phosphorylceramide synthase by aureobasidin in Candida and Aspergillus Species Antimicrob. Agents Chemother. 2000 44 651 653 10.1128/AAC.44.3.651-653.2000 10681333 124. Levery S. Momany M. Lindsey R. Toledo M. Shayman J. Fuller M. Brooks K. Doong R. Straus A. Takahashi H. Disruption of the glucosylceramide biosynthetic pathway in Aspergillus nidulans and Aspergillus fumigatus by inhibitors of UDP-Glc:ceramide glucosyltransferase strongly affects spore germination, cell cycle, and hyphal growth FEBS Lett. 2002 525 59 64 10.1016/S0014-5793(02)03067-3 12163162 125. Georgopapadakou N. Antifungals targeted to sphingolipid synthesis: Focus on inositol phosphorylceramide synthase Expert Opin. Inv. Drug 2000 9 1787 1796 10.1517/13543784.9.8.1787 11060777 126. Da Silva A. Rodrigues M. Farias S. Almeida I. Pinto M. Barreto-Bergter E. Glucosylceramides in colletotrichum gloeosporioides are involved in the differentiation of conidia into mycelial cells FEBS Lett. 2004 561 137 143 10.1016/S0014-5793(04)00156-5 15013765 127. Garcia-Ranea J. Valencia A. Distribution and functional diversification of the ras super family in Saccharomyces cerevisiae FEBS Lett. 1998 434 219 225 10.1016/S0014-5793(98)00967-3 9742927 128. Roy S. Plowman S. Rotblat B. Prior I. Muncke C. Grainger S. Parton R. Henis Y. Kloog Y. Hancock J. Individual palmitoyl residues serve distinct roles in H-Ras trafficking, microlocalization, and signaling Mol. Cell Biol. 2005 25 6722 6733 10.1128/MCB.25.15.6722-6733.2005 16024806 129. Abdallah Q. Fortwendel J. Exploration of Aspergillus fumigatus Ras pathways for novel antifungal drug targets Front. Microbiol. 2015 6 128 10.3389/fmicb.2015.00128 25767465 130. Fortwendel R.J. Ras-mediated signal transduction and virulence in human pathogenic fungi Fungal Genom. Biol. 2012 2 105 10.4172/2165-8056.1000105 24855584 131. Maurer T. Garrenton L. Oh A. Pitts K. Anderson D. Skelton N. Fauber B. Pan B. Malek S. Stokoe D. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity Proc. Natl. Acad. Sci. USA 2012 109 5299 5304 10.1073/pnas.1116510109 22431598 132. Appels N. Beijnen J. Schellens J. Development of farnesyl transferase inhibitors: A review Oncologist 2005 10 565 578 10.1634/theoncologist.10-8-565 16177281 133. Fortwendel J. Panepinto J. Seitz A. Askew D. Rhodes J. Aspergillus fumigatus rasA and rasB regulate the timing and morphology of asexual development Fungal. Genet. Biol. 2004 41 129 139 10.1016/j.fgb.2003.10.004 14732259 134. Thevelein J. Regulation of trehalose mobilization in fungi Microbiol. Rev. 1984 48 42 59 10.1128/MMBR.48.1.42-59.1984 6325857 135. Elbein A. New insights on trehalose: A multifunctional molecule Glycobiology 2003 13 17 27 10.1093/glycob/cwg047 12626396 136. Thammahong A. Puttikamonkul S. Brennan J. Perfect R. Central role of the trehalose biosynthesis pathway in the pathogenesis of human fungal infections: Opportunities and challenges for therapeutic development Microbiol. Mol. Biol. Rev. 2017 81 e00053-16 10.1128/MMBR.00053-16 28298477 137. Ngamskulrungroj P. Himmelreich U. Breger J. Wilson C. Chayakulkeeree M. Krockenberger M. Malik R. Daniel H. Toffaletti D. Djordjevic J. The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii Infect. Immun. 2009 77 4584 4596 10.1128/IAI.00565-09 19651856 138. Perfect J. Tenor J. Miao Y. Brennan R. Trehalose pathway as an antifungal target Virulence 2016 8 143 149 10.1080/21505594.2016.1195529 27248439 139. Fillinger S. Chaveroche M. van Dijck P. de Vries R. Ruijter G. Thevelein J. d’Enfert C. Trehalose is required for the acquisition of tolerance to a variety of stresses in the filamentous fungus Aspergillus nidulans The GenBank accession number for the sequence reported in this paper is AF043230 Microbiology 2001 147 1851 1862 10.1099/00221287-147-7-1851 11429462 140. Svanström Å. van Leeuwen M. Dijksterhuis J. Melin P. Trehalose synthesis in Aspergillus niger : Characterization of six homologous genes, all with conserved orthologs in related species BMC Microbiol. 2014 14 90 10.1186/1471-2180-14-90 24725382 141. Al-Bader N. Vanier G. Liu H. Gravelat F. Urb M. Hoareau C. Campoli P. Chabot J. Filler S. Sheppard D. Role of trehalose biosynthesis in Aspergillus fumigatus development, stress response, and virulence Infect. Immun. 2010 78 3007 3018 10.1128/IAI.00813-09 20439478 142. Thammahong A. Dhingra S. Bultman K. Kerkaert J. Cramer R. An Ssd1 homolog impacts trehalose and chitin biosynthesis and contributes to virulence in Aspergillus fumigatus Msphere 2019 4 e00244-19 10.1128/mSphere.00244-19 31068436 143. Gustin M. Albertyn J. Alexander M. Davenport K. MAP kinase pathways in the yeast Saccharomyces cerevisiae Microbiol. Mol. Biol. Rev. 1988 62 1264 1300 10.1128/MMBR.62.4.1264-1300.1998 9841672 144. Maeda T. Takekawa M. Saito H. Activation of yeast PBS2 MAPKK by MAPKKKs or by binding of an SH3-containing osmosensor Science 1995 269 554 558 10.1126/science.7624781 7624781 145. Cobb M. Goldsmith E. How MAP kinases are regulated J. Biol. Chem. 1995 270 14843 14846 10.1074/jbc.270.25.14843 7797459 146. Ji Y. Yang F. Ma D. Zhang J. Wan Z. Liu W. Li R. HOG-MAPK signaling regulates the adaptive responses of Aspergillus fumigatus to thermal stress and other related stress Mycopathologia 2012 174 273 282 10.1007/s11046-012-9557-4 22678624 147. Ma D. Li R. Current understanding of HOG-MAPK pathway in Aspergillus fumigatus Mycopathologia 2012 175 13 23 10.1007/s11046-012-9600-5 23161019 148. Bahn Y. Master and commander in fungal pathogens: The two-component system and the HOG signaling pathway Eukaryot. Cell 2008 7 2017 2036 10.1128/EC.00323-08 18952900 149. Buschart A. Burakowska A. Bilitewski U. The fungicide fludioxonil antagonizes fluconazole activity in the human fungal pathogen Candida albicans J. Med. Microbiol. 2012 61 1696 1703 10.1099/jmm.0.050963-0 22918865 150. Kojima K. Bahn Y. Heitman J. Calcineurin, Mpk1 and Hog1 MAPK pathways independently control fludioxonil antifungal sensitivity in Cryptococcus neoformans Microbiology 2006 152 591 604 10.1099/mic.0.28571-0 16514140 151. Ziogas B. Kalamarakis A. Phenylpyrrole Fungicides: Mitotic Instability in Aspergillus nidulans and Resistance in Botrytis cinerea J. Phytopathol. 2001 149 301 308 10.1046/j.1439-0434.2001.00617.x 152. Newman D. Cragg G. Snader K. Natural products as sources of new drugs over the period 1981−2002 J. Nat. Prod. 2003 66 1022 1037 10.1021/np030096l 12880330 153. Ostrosky-Zeichner L. Casadevall A. Galgiani J. Odds F. Rex J. An insight into the antifungal pipeline: Selected new molecules and beyond Nat. Rev. Drug Discov. 2010 9 719 727 10.1038/nrd3074 20725094 154. Donadu M. Usai D. Marchetti M. Usai M. Mazzarello V. Molicotti P. Montesu M. Delogu G. Zanetti S. Antifungal activity of oils macerates of North Sardinia plants against Candida species isolated from clinical patients with candidiasis Nat. Prod. Res. 2019 10.1080/14786419.2018.1557175 155. Da Silva Bomfim N. Kohiyama C. Nakasugi L. Nerilo S. Mossini S. Romoli J. Graton Mikcha J. Abreu Filho B. Machinski M. Jr. Antifungal and antiaflatoxigenic activity of rosemary essential oil (Rosmarinus officinalis L.) against Aspergillus flavus Food Addit. Contam. Part A 2019 37 153 161 10.1080/19440049.2019.1678771 31644378 156. Powers C. Satyal P. Mayo J. McFeeters H. McFeeters R. Bigger data approach to analysis of essential oils and their antifungal activity against Aspergillus niger , Candida albicans , and Cryptococcus neoformans Molecules 2019 24 2868 10.3390/molecules24162868 31394798 157. Valiante V. Monteiro M. Martín J. Altwasser R. El Aouad N. González I. Kniemeyer O. Mellado E. Palomo S. de Pedro N. Hitting the caspofungin salvage pathway of human-pathogenic fungi with the novel lasso peptide Humidimycin (MDN-0010) Antimicrob. Agents Chemother. 2015 59 5145 5153 10.1128/AAC.00683-15 26055366